Vectus Biosystems Limited (ASX:VBS)
Australia · Delayed Price · Currency is AUD 0.1350
-0.0100 (-6.90%)
Sep 18, 2026, 3:38 PM AEST
Vectus Biosystems Company Description
Vectus Biosystems Limited engages in the medical research and development activities in Australia.
The company develops a pipeline of antifibrotic assets targeting cardiovascular, renal and liver fibrosis to address diseases driven by pathological tissue scarring.
Its lead compound is VB0004, currently under phase Ib clinical human trial, which targets the prevention and reversal of fibrosis in the lungs, heart, and kidneys.
The company was incorporated in 2005 and is based in Rosebery, Australia.
Vectus Biosystems Limited
| Country | Australia |
| Founded | 2005 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Tara Speranza |
Contact Details
Address: 26-34 Dunning Avenue Rosebery, NSW 2018 Australia | |
| Phone | 61 2 8344 1300 |
| Website | vectusbiosystems.com.au |
Stock Details
| Ticker Symbol | VBS |
| Exchange | Australian Securities Exchange |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| ISIN Number | AU000000VBS9 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Tara Speranza | Chief Executive Officer and Chief Technology Officer |
| Robert John Waring BEc, CA, FAICD, FCIS, FFin | Company Secretary |
| Prof. Graham Jon MacDonald AM, BS, BSc (Med), FANZCC, FRACP, FRCP, M.D. | Consultant |